Editor's Choice
Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program03 Apr 2023
Arch Biopartners Inc. has announced that it is receiving advisory services and up to $4,000,000 in funding from the National... Continue Reading
|
Latest Data for Karuna’s Schizophrenia Drug Spark Investor Concern27 Mar 2023
Karuna Therapeutics’ stock dropped more than 19% in 48 hours after positive results from a Phase III trial of KarXT,... Continue Reading
|
Evotec Receives US$ 6.6 M Grant for Drug Discovery in Tuberculosis27 Mar 2023
Evotec SE has received a $6.6 million grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis... Continue Reading
|
Sparta Science Raises A New Round of Funding to Help Organizations Optimize Movement Health Outcomes at Scale27 Mar 2023
Sparta Science, a Movement Health Intelligence company, has announced an additional funding round led by Spring Lake Equity Partners. General... Continue Reading
|
Why Patient Trust is Key for Burgeoning Retail Healthcare Providers27 Mar 2023
In a recent interview with MobiHealthNews, Christopher Lis, managing director of global healthcare intelligence at J.D. Power, discussed the recent... Continue Reading
|
Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program27 Mar 2023
Arch Biopartners, a clinical stage biotech company focused on developing therapeutics targeting organ inflammation, announced that it will receive up... Continue Reading
|
USFDA Accepts Glenmark’s Application to Initiate a Human Trial of Molecules for Advanced Solid Tumors and Lymphomas20 Mar 2023
Glenmark Specialty SA on Thursday announced that it has received acceptance from the U.S. Food and Drug Administration (FDA) on... Continue Reading
|
Immuno-Oncology Pipeline Cuts Explained20 Mar 2023
As more Q4 and full-year 2022 financial statements are released, immuno-oncology pipelines continue to be slashed. There are myriad factors... Continue Reading
|
Janssen’s Novel Dengue Antiviral Demonstrates ‘strong Protection’ in Pre-Clinical Data20 Mar 2023
The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced on Thursday the publication of new data in the journal... Continue Reading
|
Eli Lilly Forays in the O Dermatological Space in and India Launches Psoriasis Drug20 Mar 2023
New Delhi: The leading biopharma major, Eli Lilly has launched Copellor®(Ixekizumab) in India for the treatment of adults with moderate-to-severe... Continue Reading
|